The invention discloses benzothiophene alkanol piperazine derivatives and their use as antidepressants. The invention discloses the said benzothiophene alkanol piperazine derivative having triple inhibition effect on the reuptake of 5-HT NA and DA. Compared with clinical used antidepressants so far having single target e.g. desipramine and fluoxetine and clinical used antidepressants so far having double targets e.g venlafaxine and duloxetine the said benzothiophene alkanol piperazine derivative...

A controlled release dosage form of venlafaxine that comprises an immediate release pellet and an extended release pellet.

Methods of preparing and compositions comprising derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including but not limited to affective disorders such as depression bipolar and manic disorders attention deficit disorder attention deficit disorder with hyperactivity Parkinson's disease epilepsy cerebral function disorders obesity and weight gain incontinence dementia and related disorders.

The patent discloses an asymmetric synthesis of (-)-venlafaxine using an organocatalyst via a unified strategy employing organcatalytic Michael addition, regio-selective dehydration and selective epoxide ring opening.

The present invention relates to controlled porous osmotic pump tablets of high permeable drugs and the preparation process thereof. The controlled porosity osmotic pump tablets do not need to be drilled by laser, but provides controlled porosity for drug release by adding a suitable quantity of pore-forming agents into the semipermeable membrane. In specific embodiments, the present invention relates to controlled porous osmotic pump tablets comprising venlafaxine or metoprolol or pharmaceutica...

The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) gamma-linolenic acid (GLA) and/or the pharmaceutically acceptable deri...